Akums Drugs [AKUMS] vs Eris Lifesciences [ERIS] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Akums Drugs & Pharmaceuticals Ltd. wins in 10 metrics, Eris Lifesciences Ltd. wins in 8 metrics, with 0 ties. Akums Drugs & Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Akums Drugs & Pharmaceuticals Ltd. | Eris Lifesciences Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.39 | 44.25 | Akums Drugs & Pharmaceuticals Ltd. |
| Price-to-Book Ratio | 2.58 | 6.15 | Akums Drugs & Pharmaceuticals Ltd. |
| Debt-to-Equity Ratio | 2.85 | 68.19 | Akums Drugs & Pharmaceuticals Ltd. |
| PEG Ratio | 15.45 | 2.33 | Eris Lifesciences Ltd. |
| EV/EBITDA | 13.90 | 17.91 | Akums Drugs & Pharmaceuticals Ltd. |
| Profit Margin (TTM) | 7.47% | 14.06% | Eris Lifesciences Ltd. |
| Operating Margin (TTM) | 9.25% | 26.38% | Eris Lifesciences Ltd. |
| EBITDA Margin (TTM) | 9.25% | 26.38% | Eris Lifesciences Ltd. |
| Return on Equity | 11.04% | 10.75% | Akums Drugs & Pharmaceuticals Ltd. |
| Return on Assets (TTM) | 8.22% | 5.00% | Akums Drugs & Pharmaceuticals Ltd. |
| Free Cash Flow (TTM) | $1.93B | $9.10B | Eris Lifesciences Ltd. |
| Dividend Yield | N/A | 0.41% | N/A |
| 1-Year Return | -8.21% | -11.56% | Akums Drugs & Pharmaceuticals Ltd. |
| Price-to-Sales Ratio (TTM) | 1.91 | 6.31 | Akums Drugs & Pharmaceuticals Ltd. |
| Enterprise Value | $66.39B | $217.40B | Eris Lifesciences Ltd. |
| EV/Revenue Ratio | 1.56 | 7.09 | Akums Drugs & Pharmaceuticals Ltd. |
| Gross Profit Margin (TTM) | 41.48% | 72.12% | Eris Lifesciences Ltd. |
| Revenue per Share (TTM) | $278 | $225 | Akums Drugs & Pharmaceuticals Ltd. |
| Earnings per Share (Diluted) | $20.89 | $31.54 | Eris Lifesciences Ltd. |
| Beta (Stock Volatility) | N/A | -0.14 | N/A |
Akums Drugs & Pharmaceuticals Ltd. vs Eris Lifesciences Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Akums Drugs & Pharmaceuticals Ltd. | 2.78% | 0.97% | -3.34% | 15.68% | 28.42% | 21.20% |
| Eris Lifesciences Ltd. | -2.13% | 3.43% | 3.21% | 2.87% | -10.51% | -6.95% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Akums Drugs & Pharmaceuticals Ltd. | -8.21% | -34.69% | -34.69% | -34.69% | -34.69% | -34.69% |
| Eris Lifesciences Ltd. | -11.56% | 119.21% | 94.70% | 132.59% | 132.59% | 132.59% |
Performance & Financial Health Analysis: Akums Drugs & Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | AKUMS | ERIS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹82.60B | ₹193.36B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 231,185 | 174,049 |
| 90 Day Avg. Volume | 184,565 | 106,619 |
| Last Close | ₹555.50 | ₹1,367.30 |
| 52 Week Range | ₹409.30 - ₹597.00 | ₹1,200.00 - ₹1,910.00 |
| % from 52W High | -6.95% | -28.41% |
| All-Time High | ₹1,175.90 (Aug 19, 2024) | ₹1,910.00 (Jun 09, 2025) |
| % from All-Time High | -52.76% | -28.41% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.11% |
| Quarterly Earnings Growth | 0.02% | 0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.14% |
| Operating Margin (TTM) | 0.09% | 0.26% |
| Return on Equity (TTM) | 0.11% | 0.11% |
| Debt to Equity (MRQ) | 2.85 | 68.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹205.37 | ₹226.84 |
| Cash per Share (MRQ) | ₹108.02 | ₹5.49 |
| Operating Cash Flow (TTM) | ₹2.59B | ₹7.57B |
| Levered Free Cash Flow (TTM) | ₹3.38B | ₹3.52B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.41% |
| Last 12-Month Dividend | N/A | ₹7.35 |
Valuation & Enterprise Metrics Analysis: Akums Drugs & Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | AKUMS (Apr 24, 2026) | ERIS (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.39 | 44.25 |
| Forward P/E | 21.47 | 27.76 |
| PEG Ratio | 15.45 | 2.33 |
| Price to Sales (TTM) | 1.91 | 6.31 |
| Price to Book (MRQ) | 2.58 | 6.15 |
| Market Capitalization | ||
| Market Capitalization | ₹82.60B | ₹193.36B |
| Enterprise Value | ₹66.39B | ₹217.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.56 | 7.09 |
| Enterprise to EBITDA | 13.90 | 17.91 |
| Risk & Other Metrics | ||
| Beta | N/A | -0.14 |
| Book Value per Share (MRQ) | ₹205.37 | ₹226.84 |
Financial Statements Comparison: Akums Drugs & Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | AKUMS (2025) | ERIS (2025) |
|---|---|---|
| Revenue/Sales | 40.71B | 28.79B |
| Cost of Goods Sold | 24.66B | 7.30B |
| COGS % of Revenue | 60.6% | 25.4% |
| Gross Profit | 16.05B | 21.49B |
| Gross Margin | 39.4% | 74.6% |
| Research & Development | N/A | 24.40M |
| Operating Income (EBIT) | 3.11B | 7.03B |
| Operating Margin | 7.6% | 24.4% |
| EBITDA | 5.05B | 10.33B |
| EBITDA Margin | 12.4% | 35.9% |
| Pre-Tax Income | 3.45B | 4.89B |
| Pre-Tax Income % of Revenue | 8.5% | 17.0% |
| Income Tax | 14.76M | 1.14B |
| Income Tax % of Revenue | 0.0% | 4.0% |
| Net Income (Profit) | 3.44B | 3.75B |
| Profit Margin | 8.4% | 13.0% |
Balance Sheet & Liquidity Metrics
| Metric | AKUMS (2025) | ERIS (2025) |
|---|---|---|
| Cash & Equivalents | 1.01B | 2.00B |
| Total Current Assets | 22.75B | 12.23B |
| Total Current Assets % of Revenue | 55.9% | 42.5% |
| Total Current Liabilities | 8.94B | 13.81B |
| Total Current Liabilities % of Revenue | 22.0% | 48.0% |
| Long-Term Debt | 673.27M | 17.82B |
| Long-Term Debt % of Revenue | 1.7% | 61.9% |
| Total Shareholders Equity | 30.64B | 32.72B |
| Retained Earnings | 18.29B | 27.93B |
| Retained Earnings % of Revenue | 44.9% | 97.0% |
| Property, Plant & Equipment | 2.29B | 2.36B |
Cash Flow Statement Comparison
| Metric | AKUMS (2025) | ERIS (2025) |
|---|---|---|
| Operating Cash Flow | 2.59B | 7.57B |
| Operating Cash Flow % of Revenue | 6.4% | 26.3% |
| Capital Expenditures | -2.64B | -1.55B |
| Free Cash Flow | 1.93B | 9.10B |
| FCF Margin | 4.7% | 31.6% |
| Debt Repayment | -1.24B | -18.34B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AKUMS | ERIS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 153.10M | 138.54M |
| Float Shares | 30.36M | 43.42M |
| % Held by Insiders | 80.17% | 68.05% |
| % Held by Institutions | 13.60% | 21.83% |
| % Held by Public | 6.23% | 10.12% |
Dividend Analysis & Yield Comparison: Akums Drugs & Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | AKUMS | ERIS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹7.35 |
| Last 12-Month Dividend Yield | N/A | 0.41% |
| 3-Year Avg Annual Dividend | N/A | ₹4.90 |
| 3-Year Avg Dividend Yield | N/A | 0.82% |
| 3-Year Total Dividends | N/A | ₹14.70 |
| Ex-Dividend Date | N/A | Feb 13, 2025 |